JSPR צמיחת רווחי EPS רבעונית Jasper Therapeutics, Inc.
Exclusive patents for transplant preparation create a significant barrier to entry for competitors. The quarterly EPS growth history displayed on GURU.Markets shows that this metric stands at 93.70. Future revenues are based on the commercialization of antibodies for bone marrow cleansing, although the model currently relies on venture capital due to a lack of pricing power during the testing phase for Jasper Therapeutics (JSPR).
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_JSPR_-_Jasper-Therapeutics_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "jaspertherapeutics.com (JSPR): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 15.11.2026 | 👁️GURU.Markets👁️")
jaspertherapeutics.com (JSPR) - פילוחי מדדים ודוחות פיננסיים
Diversification of clinical developments in oncology and immunology minimizes risks for Jasper Therapeutics (JSPR), which is reflected in the quarterly growth dynamics of earnings per share. This indicator measures the percentage change in net income per common share relative to the previous period, allowing investors to assess the pace of business scaling and adjust the fair value calculation of the asset.
